NDAQ
67
4
IBM
54
4
ZION
63
2
TROW
31
2
BXP
42
-2
NEE
41
3
ESS
39
-5
JPM
66
4
PLD
35
3
CL
50
2
VTR
58
3
SBUX
39
3
SLB
35
3
WEC
77
2
CMCSA
42
3
SIG
38
6
HON
60
7
TRIP
44
-2
O
30
2
ADM
40
-4
NDAQ
67
4
IBM
54
4
ZION
63
2
TROW
31
2
BXP
42
-2
NEE
41
3
ESS
39
-5
JPM
66
4
PLD
35
3
CL
50
2
VTR
58
3
SBUX
39
3
SLB
35
3
WEC
77
2
CMCSA
42
3
SIG
38
6
HON
60
7
TRIP
44
-2
O
30
2
ADM
40
-4
Financhill
Back

InMed Pharmaceuticals 10K Form

Sell
47

INM
InMed Pharmaceuticals

Last Price:
$2.98
Seasonality Move:
53.17%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive INM News And Ratings

See the #1 stock for the next 7 days that we like better than INM

INM Financial Statistics

Sales & Book Value

Annual Sales: $4.6M
Cash Flow: $-2.5M
Price / Cash Flow: 0
Annual Sales: $8.54
Price / Book: 0.58

Profitability

EPS (TTM): -13.75000
Net Income (TTM): $-7.9M
Gross Margin: $1.1M
Return on Equity: -83.02%
Return on Assets: -66.61%

InMed Pharmaceuticals Earnings Forecast

Key InMed Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 24 years for INM is 23.94%.
  • The Selling, General & Administrative Expenses for INM have been equal to 114.20% of Gross Profit Margin.
  • The Research & Development expenses have been 81.89% of Revenue.
  • Per Share Earnings over the last 24 years have been positive in 12 years.

InMed Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: INM
Website: inmedpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.05
Quick Ratio: 2.06

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

INM Technical Analysis vs Fundamental Analysis

Sell
47
InMed Pharmaceuticals (INM) is a Sell

Is InMed Pharmaceuticals a Buy or a Sell?